Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

By W. Hueber, D. Patel, T. Dryja, A. Wright, I. Koroleva, G. Bruin, C. Antoni, Z. Draelos, M. Gold, P. Durez and 12 more. Science Translational Medicine, 2010

908 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/90314954b901794fe28a6a9257373969670e2789

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. C. A. Dinarello

In Immunology

1. D. Brenner
2. Y. Iwakura
3. P. Miossec
4. H. Ishigame
5. S. Nakae

In Pathology and Forensic Medicine

1. Y. Iwakura
2. H. Ishigame

Citations in the corpus

• Functional specialization of interleukin-17 family members. (2011, background): “Nonetheless, recent clinical studies suggest the involvement of IL-17A in psoriasis (Hueber et al., 2010).”
• The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 (2020, neutral): “Kawasaki disease, but not MIS-C, is associated with robust IL17A-mediated inflammation, and IL-17A blocking agents, such as secukinumab (Hueber et al., 2010), could be considered in severe Kawasaki disease patients in future trials but perhaps less relevant to MIS-C.”
• Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. (2012, background): “AIN457 induced clinically relevant responses of variable magnitude in RA, psoriasis and uveitis patients.(101) Similarly, LY2439821 MAb used in combination with oral disease-modifying anti-rheumatic drugs, improved clinical signs and symptoms of RA, with no strong adverse effects.”
• Liver inflammation and fibrosis. (2017, background): “Anti–IL-17 biological therapies are currently in clinical trials for autoimmune inflammatory diseases and may be applicable in liver inflammation and fibrosis (81).”